RGC Investors Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, May 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited (“Regencell” or “the Company”) (NASDAQ: RGC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before June 23, 2026.

Originally published on xprmedia.binwus.com, part of the BLOX Digital Content Exchange.

Locations

Recommended for you